ROIV
NASDAQ HealthcareRoivant Sciences Ltd. - Common Shares
Biotechnology
Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody that targets the neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases. The company's lead program consists of mosliciguat, an inhaled sGC activator for the treatment of pulmonary hypertension associated with interstitial lung disease and other cardiopulmonary diseases. In addition, the company offers delivery platforms comprising lipid nanoparticle (LNP) platform and ligand conjugate platform. Roivant Sciences Ltd. was founded in 2014 and is based in London, United Kingdom.
�� 市场数据
| 价格 | $29.83 |
|---|---|
| 成交量 | 6,037,163 |
| 市值 | 21.35B |
| 贝塔系数 | 1.210 |
| RSI（14日） | 79.4 超买 |
| 200日均线 | $19.77 |
| 50日均线 | $27.92 |
| 52周最高 | $30.33 |
| 52周最低 | $10.01 |
| Forward P/E | -25.74 |
| Price / Book | 4.96 |
🎯 投资策略评分
ROIV 在各投资策略中的评分。分数越高，越符合该策略目标。
🔍 策略解读
最佳匹配： 🐋 Institutional Whale (83/100) — 此策略 大盘、机构级别股票.
评分最低的策略： 🔪 Falling Knife (6/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →
📚 了解更多
在文本中查找 ROIV in your text
粘贴任何文章、记录或帖子 — 工具将提取 ROIV 以及每一个其他隐藏的股票代码。
免责声明：本数据仅供教育和娱乐用途，不构成金融建议。市场数据可能存在延迟。在做出投资决策之前，请始终进行自己的研究。
数据最后更新： 2026-04-17.